Background: Overexpression of HER2 is observed in 20 to 30% of breast carcinomas. The use of trastuzumab has improved the treatment of these patients, especially when it is associated with docetaxel. To optimize the use of this treatment, it seems important to select putative complete responders before treatment administration. Methods: In this study, we analyzed by quantitative PCR the expression of 28 genes in HER2-overexpressing tumors treated with trastuzumab + docetaxel-based chemotherapy. We then correlated their expression profile with those of trastuzumab-sensitive and resistant cell lines to classify tumors as having a sensitive (pCR) or resistant (non-pCR) profile. Finally, we used public datasets from the GEO website to validate the reduced gene-expression profile obtained. Results: We identified an 8-gene-expression combination that predicted the response to treatment with an accuracy of 76%. Based on public microarray data, we showed that the expression profile was specific to first-line trastuzumab + docetaxel-based treatment with an accuracy of 85%. Conclusions: Our results showed that by profiling the expression of 8 genes it was possible to predict the response to first-line trastuzumab + docetaxel-based chemotherapy. The use of cancer cell lines as the reference allowed a proper fit with the specificity of different tissues, such as lung or gastric cancers, which could also be eligible to concomitant HER2 inhibition by treatment with trastuzumab or tyrosine kinase inhibitors and docetaxel.
Background
Breast cancer is the leading cause of death by cancer in women in industrialized countries. The amplification and overexpression of human epidermal growth factor receptor 2 (HER2) is observed in 20-30% of invasive breast cancers. For locally-advanced, HER2-overexpressing breast cancer, docetaxel + trastuzumab-based neoadjuvant chemotherapy has been shown to achieve promising efficacy, with a good pathological complete response (pCR) rate, while being well tolerated in women with stage II or III HER2-positive breast cancer [1, 2] . Women who achieve a pCR have significantly improved survival [3] , but only 50% of patients with HER2-positive tumors treated with trastuzumab have pCR.
In a previous study [4] , we showed that a 28-gene signature dichotomized responses to trastuzumab + docetaxelbased regimens. In the present study, we used real-time quantitative PCR to analyze the expression of these 28 genes in 45 frozen HER2+++ tumors and 6 mammary cancer cell lines that were sensitive or resistant to trastuzumab (Additional file 1). Next, we used public datasets (GSE37946 [5] , GSE22358 [6] , and GSE42822 [7] ) to test the prediction capacity of the refined signature in different treatment regimens.
Methods

Patients and samples
We retrospectively analyzed 45 frozen HER2+++ tumors (Table 1 ). In addition, we also studied 34 FFPE HER2+++ tumors ( Table 1) . The study was conducted in accordance with the Declaration of Helsinki and approved by an Ethics Committee, the Comité Consultatif de Protection des Personnes en Recherche Biomédicale de Bourgogne. Written informed consent was obtained from all patients before enrollment. RNA was extracted from frozen samples as described previously [4] and from FFPE samples with the RNeasy FFPE kit (Qiagen) by following manufacturer's protocol.
Trastuzumab-sensitive cell lines BT474, HCC2218, UACC-812, and resistant cell lines HCC1419, HCC1954, and HCC1569 were obtained from ATCC and cultured in accordance with the supplier's instructions. The treatment of cells before RNA extraction was identical to that for patients' tumors.
Gene expression analysis
The transcriptional expression of the 28 genes was studied by real-time quantitative PCR thanks to Taqman Gene Expression Assays: PEX19 (Hs00267867), PSMD11 (Hs00160660), SENP8 (Hs00744981), PRKACA (Hs004 27274), CTNS (Hs00191849), NFE2L1 (Hs00231457), PPP2CA (Hs00427259), SENP7 (Hs00221046), SYNCRIP (Hs03044160), CEP89 (Hs01071366), SLC30A6 (Hs0021 5827), LAMA3 (Hs00165042), STX1A (Hs00270282), GPR22 (Hs01127309), GRHL2 (Hs00227745), DERL1 (Hs00225583), FAM114A2 (Hs03837084), PITPNA (Hs0 0737576), CDC14A (Hs00185432), SLC35A4 (Hs003654 08), KIAA1549 (Hs00860114), LOC158402 (Hs003274 89), ZNF146 (Hs00173196), C5orf3 (Hs00218834), WEE1 (Hs01119384), P2RX1 (Hs00175686), MFSD6 (Hs00214462), except for HNC20 transcript (Forward 5′-TGACACCCACCTGCAATTTA-3′; Reverse 5′-CAG CACTTCCCACACAAATG-3′; Probe 6-FAM-AAAAA GAAGGATGATTTGCTGC-TAMRA). Relative expression was calculated thanks to the 2 -ΔCt method with 18S expression used as the reference gene.
Public dataset study
The public dataset was downloaded from the Gene Expression Omnibus website. After the selection of genes of interest, the data were log transformed when necessary. Genes and arrays were median centered. Then, nonsupervised hierarchical clustering was performed by calculating Euclidian distances.
Statistical analysis was performed with Graph Pad Prism Software or Statview 5.0 software.
Results
Expression profile predicting response to docetaxel + transtuzumab-based neoadjuvant chemotherapy
In order to predict the response to treatment, we calculated the correlation coefficient of each tumor with each cell line. The correlation coefficient nearest to 1 corresponds to the prediction profile. As the tumor response was known, we eliminated genes one by one until we obtained the best prediction performances. This was achieved (Table 2 ) with the association of the expression of only 8 genes: CTNS, DERL-1, FAM114A2, KIAA1549, P2RX1, PITPNA, PSMD11, and WEE1. As an example, for patient A with a pCR and patient B with no pCR, the Figure 1A ). In contrast, patient B's tumor cells correlated positively with the resistant HCC1954 cell line (r = 0.85) and negatively with the sensitive BT474 cells (r = −0.25), classifying it as a resistant tumor ( Figure 1B ).
All correlation coefficients are presented in Additional file 2. Surprisingly, the expression level of these 8 genes individually was not significantly different between pCR patients and non-pCR patients ( Figure 1C) , suggesting that the combination of the expressions more than the expression of each gene individually was responsible for the prediction capacity. In parallel, we also studied corresponding FFPE samples for 34 patients of our population The expression profile is specific to response to first-line neoadjuvant docetaxel + trastuzumab-based chemotherapy
To test the prediction capacity of the combined expression of the 8 genes in different conditions, we used microarray datasets available on the GEO website. We first correlated the expression of our 8 genes with the expression of ERBB2. The 8 genes correlated significantly and positively with ERBB2 expression (Additional file 3). As our first gene expression signature was obtained from tumors treated with trastuzumab + docetaxel-based chemotherapy, we tested the prediction in patients treated with first-line neoadjuvant -docetaxel-based regimen (GSE22358), first-line neoadjuvant -trastuzumab monotherapy (GSE37946), or first-line neoadjuvant -trastuzumab + docetaxel-based chemotherapy (GSE22358). When the regimen contained docetaxel without trastuzumab (Figure 2A ) or trastuzumab alone ( Figure 2B ), our profile was not able to dichotomize tumor response. In contrast, the response of patients treated with first-line trastuzumab + docetaxel-based chemotherapy was well classified by our profile ( Figure 2C) . Indeed, the accuracy of the classification was 85% (23/27), with a sensitivity of 92% (11/12) and a specificity of 80% (12/15). Finally, it appeared that the profile was not usable for a second-line neoadjuvant trastuzumab + docetaxel-based regimen, at least after first-line neoadjuvant 5-fluorouracile + epirubicin + cyclophosphamide (GSE42822) ( Figure 2D ). This could be explained by modifications in tumor cell gene expression induced by the first treatment, which may have influenced the subsequent response of tumor cells to docetaxel + trastuzumab.
Discussion
Based on available public datasets, it appeared that the combination of the expression of only 8 genes could correctly dichotomize the response of HER2-positive advanced breast tumors to first-line trastuzumab + docetaxelbased chemotherapy. The accuracy of prediction was between 76% based on quantitative PCR data ( Table 2) and 85% based on the GEO dataset. This is equivalent to the prediction accuracy obtained with the analysis by Positron Emission Tomography of the 18 FDG uptake of tumors before treatment and after one course of chemotherapy [8, 9] . The gene expression method, however, has the advantages of a lower cost of analysis and a prediction available before the therapeutic decision. The association of trastuzumab and docetaxel is also used as an adjuvant treatment for operable breast cancer [10] , and in a small number of non-small-cell lung carcinomas [11] . In these cases, it could be interesting to evaluate the ability of our profile to predict the efficacy of adjuvant chemotherapy in breast cancer and the response of non-operable NSCLC by using activated HER2 lung cancer cell lines as the reference to avoid tissueorigin bias. Recently, HER2 overexpression was detected in 16% of gastric cancers and was associated with a poor prognosis [12] . As this sub-population of gastric cancer patients could benefit from a trastuzumab + docetaxelbased regimen [13] , it would be interesting to assess the prediction accuracy of our 8-gene expression profile in this population. Equally, our profile could be tested for the response prediction to a treatment with new HER2 tyrosine kinase inhibitors, which can be associated with docetaxel [14] , by using HER2 overexpressing gastric cancer cell lines as the reference. 
